Fig. 3. Tumour-derived IL-1B restores the infiltration of innate immune cells that may display anti-tumour functions and inhibits primary tumour growth in an IL-1B deficient microenvironment.

a, b Images and quantification of primary tumour development in IL-1B^fl/fl (n = 8 primary tumours from n = 4 mice) and IL-1B^−/− (n = 10 primary tumours from n = 5 mice) mice after intra-ductal administration of E0771 Luc2 V5 IL-1B-GFP cells. Data are mean +/− SEM, Two-way ANOVA with Sidak’s post-hoc test. c, d Quantification of F4/80⁺ macrophages (c) and CD163⁺ macrophages (d) in tumour core and periphery in IL-1B^fl/fl and IL-1B^−/− mice. Data are mean ± SEM, Two-way ANOVA with Sidak’s post hoc test. e, f Quantification of CD34⁺ blood vessels and MPO⁺ neutrophils in IL-1B^fl/fl and IL-1B^−/− mice. Data are shown as mean +/− SEM, Two-tailed unpaired t-test. g, h Images and quantification of primary tumour development in IL1R1^fl/fl (n = 18 primary tumours from n = 9 mice) and IL1R1^−/− (n = 14 primary tumours from n = 7 mice) mice after intra-ductal administration of E0771 Luc2 V5 IL-1B-GFP. Normalised data are shown as mean +/− SEM, Two-tailed unpaired t-test.